Advanced Non-small Cell Lung Cancer Clinical Trial
Official title:
Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung : a Randomized Non Comparative Phase II Trial
Lung cancer is the most commonly diagnosed malignancy and the leading cause of cancer-related mortality both in men and women worldwide. The past few years have demonstrated great progress in the field of tumor immunotherapy through agents that address mechanisms of immune escape notably, so called immune checkpoint inhibitors (ICB). Indeed, ICB have emerged as a fatal weapon in the anticancer treatment arsenal. Anti-PD-1 and anti-PD-L1 antibodies have shown promising results in several cancers including Non-small Cell Lung Cancer (NSCLC) patients. Although such ICB extend patient's survival compared with conventional systemic therapies, they fail to control cancer progression in a significant proportion of patients which can reach up to 50-60% in NSCLC. Recent literature highlights a range of factors involved in the heterogeneous responses and failures to ICB therapies. The challenge is how can ICB treatment efficacy be extended to majority patients? To respond to this question, to increase the success of immunotherapy, immuno-oncology community develops combinations approaches. The aim of these project is to evaluate the efficacy of Nivolumab plus a novel CD4Th1 inducer anti-cancer vaccine in NSCLC patients. Nivolumab (NIVO), which is an anti-PD-1 antibody, has shown promising results in 2nd line treatment for advanced NSCLC. UCPVax is a therapeutic anti-cancer vaccine based on the telomerase-derived helper peptides designed to induce strong TH1 CD4 T cell responses in cancer patients (NCT02818426).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05489731 -
VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer
|
Phase 1 | |
| Completed |
NCT01240447 -
Immunotherapy With Racotumomab Versus Support Treatment in Advanced Non-small Cell Lung Cancer Patients
|
Phase 2 | |
| Completed |
NCT00737867 -
Vinorelbine/Gemcitabine Versus Vinorelbine/Carboplatin in Advanced Non-small Cell Lung Cancer
|
Phase 3 | |
| Recruiting |
NCT05504278 -
Efficacy and Safety of IBI351 in Combination With Sintilimab ± Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation
|
Phase 1 | |
| Recruiting |
NCT05482568 -
A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06043973 -
Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance
|
Phase 3 | |
| Completed |
NCT00948675 -
Study of Participants With Advanced Non-Small Cell Lung Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT03681483 -
RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer
|
Phase 1 | |
| Terminated |
NCT05001724 -
KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05099172 -
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02133196 -
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT00874328 -
A Study of TS-1 Plus Irinotecan and Cisplatin (IP) for Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
| Completed |
NCT00487669 -
Phase II Study of Combination of Paclitaxel Poliglumex and Alimta for Advanced Non-small Cell Lung Cancer (NSCLC)
|
Phase 2 | |
| Active, not recruiting |
NCT03516981 -
A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)
|
Phase 2 | |
| Recruiting |
NCT03334864 -
Observational Cohort Study of Advanced Non-small Cell Lung Cancer (CAPTRA-LUNG)
|
||
| Terminated |
NCT00783471 -
Docetaxel Intermittent-Erlotinib (Tarceva®) In Metastatic Non Small Cell Lung Cancer (NSCLC)
|
Phase 2 | |
| Completed |
NCT00330746 -
CALC-1 (Cetuximab in Advanced Lung Cancer): Study of 2 Methods of Combining Cetuximab and Gemcitabine in Patients With Advanced Non Small-cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT03117335 -
Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung Cancer
|
Phase 3 | |
| Terminated |
NCT00345059 -
The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer
|
Phase 3 | |
| Completed |
NCT01980212 -
Tumor Relapsed Study of Serum Trxr Activity in Advanced Non-small Cell Lung Cancer
|